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Summary 
 
Introduction  
Multiple Sclerosis (MS) is a chronic, demyelinating, neurodegenerative disease of the central 
nervous system (CNS). It is predominantly the disease of the Caucasian race, more frequent in 
woman, and shows higher prevalence rates in the North. Hungary counts among the “middle-
risk” countries with a prevalence rate of 83.7/100000. Until the last two decades, MS was 
thought to only affect the quality of life the patients, yet data emerging predominantly from 
Scandinavia and North-America proved that it holds an almost threefold mortality risk and a 
~10 years reduced life expectancy, with almost two-thirds of the patients dying of MS-related 
causes. 
Based on the natural course of the disease and the attributes of activity and progression, MS 
can be categorized to two basic clinical courses: relapsing and progressive MS. Relapsing MS 
can be either active or inactive relapsing-remitting (RRMS) course, or inactive or active 
clinically isolated syndrome (CIS – in the latter case, it means conversion to RRMS). 
Progressive MS can be either primary or secondary progressive, which can be active and 
progressing, inactive but progressing, non-progressing but active, or inactive and non-
progressing. The older concept of “benign” MS has been abandoned, as several studies 
showed that after a longer follow-up periods, most of the “benign” patients reach high EDSS 
scores and converted to secondary progressive course. This led to the search of those unseen 
symptoms that can be present during the initial, seemingly benign phase of MS. Studies found 
that many of these patients suffer from psychopathological symptoms, such as cognitive 
impairment (CI), fatigue, depression and anxiety. CI is a frequent, yet underdiagnosed 
symptom of MS with prevalence rates 43-70%. It seriously worsens the quality of life of the 
patients, being one of the most important factors for unemployment. MS patients however do 
not become demented; the most frequently affected domains are information processing 
speed, visual and verbal memory. Some scattered data showed, that men seemingly are more 
often affected. However, measurement of CI is not easy as it requires specialists, special 
equipment and it is highly time-consuming. Thus, in 2011, a committee of neurologist and 
neuropsychologists created the Brief International Cognitive Assessment for Multiple 
Sclerosis (MS) battery for the quick, yet still sensitive screening of CI in MS. Fatigue is the 
most common symptom of MS, with virtually every patient experiencing it during some 
period. Depression is also very frequent, with a life-time prevalence nearing 50%. Both are 
reported to be overwhelmingly important factors regarding the quality of life of the patients. 
The evaluation of both symptoms can be done by self-report: one of the most sensitive and 
widely-used battery for fatigue is the Fatigue Impact Scale (FIS) and the Beck’s Depression 
Inventory (BDI-II) for depression. 
Aims 
In our three separate assessments, we aimed to determine the causes of death and the 
mortality risk of the Hungarian MS patients; to validate the BICAMS battery to Hungarian 
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and to give the prevalence of CI among the Hungarian MS patients and assess any potential 
risk factors of developing it.  
 
Patients and methods 
In our first evaluation, we examined 740 patients treated at the MS outpatient unit of the 
Department of Neurology of the University of Szeged, of which 121 died during the period. 
The causes of death were established from the pathological records or the medical certificates 
of the cause of death. We calculated the standardized mortality ratios (SMR) and assessed the 
survival times with Gehan-Breslow test. In our validation study of the BICAMS battery, we 
enrolled 65 RR-MS patients and 65 age, sex and education matched healthy control (HC) 
subjects whom were tested retested after 3 weeks. The patients also completed the FIS battery. 
Group differences were calculated by paired sample T-tests, the test-retest reliability was 
measured by intraclass correlation coefficients. To analyse the difference between the test-
retest performances, two-way repeated measures ANOVA - with the BICAMS battery being 
the single composite outcome - and one-way repeated measures ANOVA were utilized. To 
assess impact of fatigue on cognition, we examined the correlations between the BICAMS 
and the FIS batteries. In our study of the prevalence and risk factors of CI, we enrolled 553 
RRMS and CIS patients from three Hungarian MS centres (Szeged, Budapest, and Eger). Age 
at screening, age at disease onset, disease duration, EDSS score, sex and educational levels 
were the analysed social-demographic factors. The BICAMS battery was used to assess CI, 
the BDI-II battery to assess depression. We used Fisher exact tests, chi-square tests and one-
way ANOVA to find differences between the key demographic and clinical data and utilized a 
logistic regression model to assess the predictive factors. 
Results 
Two-third of our patients died of MS-related causes. The overall SMR was 2.52, with solely 
MS-related causes being the reason for this elevated mortality risk. We found negligible 
difference between the sexes, yet regarding the different courses, PPMS patients’ SMR was 
4.10, significantly higher than RR/SPMS patients (2.34; p<0.001). PPMS patients survived 
for less than half the time (14 years) than RR/SPMS patients (35 years; p<0.001).  
During our validation study, we found significant difference (p≤0.001, p=0.017 in the first 
CVLT-II assessment) between the performance of MS patients and members of the HC group 
in both sessions. The test-retest correlation were very strong (r>0.8; p<0.001; r=0.678, 
p<0.001 between the CVLT-II assessments). We found that the HC group performed 
significantly (p=0.020) better during the retest as compared to their original performance than 
the patients and this difference can solely be attributed to the  CVLT-II performances. There 
was significant negative correlation between the patients' cognitive function and fatigue 
scores (r<-0.3, p<0.05).  
In our epidemiological survey of cognition, 316 (57.1%) patients had CI. Sex, educational 
level and EDSS score were all significant predictors (OR: 2.71, p<0.001; OR: 1.94, p=0.023; 
OR: 0.47, p=0.003 respectively). CI was significantly (p<0.001) more frequent among men 
(70.1%) than women (52.0%) and educational level and EDSS score were only a significant 
predicting factor among women. The prevalence of cognitive dysfunction among women with 
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college or university degree was significantly (p<0.001) less common (39.4%) than in women 
lower educational levels (57.4% - 12-15 years of learning; and 66.7%- <12 years of learning). 
Women with higher EDSS scores (>2 points) had a prevalence of 69.9%, while in women 
with EDSS score between 0-2 points, the prevalence was significantly lower (42.8%, 
p<0.001). No such differences were found among men.  
Discussion and conclusion 
Our survey yielded similarly high ratio of MS-related cause of death and higher mortality risk 
in the Hungarian MS patients than in earlier assessments from Nordic countries and North-
America, with a markedly elevated risk among PPMS patients. Our survey highlights that this 
higher mortality risk does not depend on any outside factors, only on the disease itself with us 
being the first group to give such data from Central-Eastern Europe.  
We showed, that the Hungarian version of the BICAMS battery, the third validated version 
during the time of publication, is valid and reliable tool for measuring CI in MS. We also 
found some connection between subjective fatigue and CI, that could warrant further 
assessments of the relationship between the two psychopathological symptoms. 
We found a similarly high prevalence of CI among our patients as in other, earlier 
assessments. Men are more susceptible to CI, and it seems, that higher educational level and 
lower EDSS scores are only associated with better cognitive performance in women. We are 
the first to report, however, such differences between the sexes regarding the predictive 
factors of CI among MS patients.  
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I.  Introduction 
Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central 
nervous system (CNS), characteristically displaying signs of inflammation, demyelination and 
axonal damage (Trapp et al., 1998). Its name originates from the first pathological findings 
after the dissection of diseased patients’ brain: several plaques are macroscopically visible in 
different parts of the CNS (multiple) and these plaques are stiffer to touch than normal brain 
tissue (sclerosis). It is one of the leading reasons of disability among young adults and it 
seriously worsens the quality of life (QoL) of patients: when compared to other autoimmune 
diseases, people with MS (PwMS) perceive their QoL to be the worst (Rudick et al., 1992). 
 
I.1. Epidemiology of MS 
On the general basis, MS is considered to be a rare disease: there are approximately 2.5 
million patients worldwide (Browne et al., 2014). Yet, there are several factors determining 
susceptibility to it. It is generally the disease of the Caucasian race: among Africans and 
African-Americans, it is much rarer, just as among the Gypsy population of Hungary (Dobson 
and Giovannoni, 2019; Kalman et al., 1991). It also shows a North-South gradient as the 
prevalence of MS is the highest in Scandinavia, Canada and the Northern parts of the United 
States of America (with prevalence rates well over 200/100 000), while it gradually decrease 
with nearing the equator, where it is a rarity (Beck et al., 2005; Heydarpour et al., 2015; 
Mackenzie et al., 2014; Simonsen et al., 2017). Similarly to other autoimmune diseases, 
women are more often affected; the man-women ration is 1:2-3 (Bostrom et al., 2013; Celius 
and Smestad, 2009; Zsiros et al., 2014). Also, age is an important factor: the disease generally 
manifests in early adulthood or in the early middle ages (20-45 years) in approximately 80% 
of the cases (Confavreux et al., 1980). Yet, in ~10% of the patients, the first symptoms of MS 
appear much earlier, in childhood; and in about 10% of the patients, the disease starts at an 
older age (>50 years) (Louapre et al., 2017; Sandi et al., 2018).  
Hungary counts among the “middle-risk” countries considering the prevalence of the disease. 
The first epidemiological data arose in 1961. According to this report, the crude prevalence of 
MS was 20/100 000 in Hungary (Lehoczky and Halasy-Lehoczky, 1961). In the ‘80s, Pálffy et 
al. found that the prevalence of MS in Baranya County was 37/100 000 (Prange et al., 1986). 
In Csongrád County, the crude prevalence of MS was shown to be 62/100 000 by Bencsik et 
al. in 1998 (Bencsik et al., 1998). In 2013, a new epidemiological study was conducted that 
reported the standardized prevalence of MS in Csongrád County to be 83.7/100 000 (Zsiros et 
al., 2014).  
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This increase in prevalence rate however is not surprising. Early diagnostic criteria – in the 
absence of magnetic resonance imaging (MRI), liquor diagnostic tools etc. – only relied on 
the clinical manifestations of the disease, stating that MS was ultimately a pathological 
diagnosis (Schumacher et al., 1965). In the ‘80s, with the creation of the Poser diagnostic 
criteria, which placed the patients into definitive MS, probable MS and not MS categories 
based on the clinical course and paraclinical findings, the diagnosis became more definitive 
and could be achieved earlier than before (Poser et al., 1983). With MRI being widely 
utilized, the new McDonald criteria relied heavily on its use, permitting the diagnosis of MS 
after only one clinical attack (McDonald et al., 2001). Since 2001, this diagnostic criteria has 
been revised three times, last time in 2017 (Polman et al., 2011; Polman et al., 2005; 
Thompson et al., 2018). As the technology of MRI evolved, it started to play a pivotal role not 
only in the diagnosis of the disease, but for the regular follow-up of disease activity, which is 
extremely important for measuring the efficacy of the utilizable disease modifying therapies 
(DMTs). In 2016, the MAGNIMS group published their own MRI diagnostic guideline, 
further specifying the MRI criteria for early diagnosis and follow-up (Filippi et al., 2016). All 
these evolution in the diagnostic tools have culminated in the earlier and surer diagnosis of 
MS, which in turn led to an increasing prevalence and incidence worldwide. 
 
I.2. Mortality in MS 
For until the last three decades, MS was considered to be a disease only affecting the patients’ 
QoL and having no effect on the lifespan and mortality. Since however, this view has radically 
changed. 
The first study dedicated to the topic was carried out in Scotland and was published in 1987 
(Phadke, 1987). It found, that approximately 2/3 of the patients die due to MS-related causes 
(Phadke, 1987). As MS progresses, it leads to severe disability and patients become immobile 
and bedridden. Thus, the causes of death (CoD) are the complications of long-term bed 
riddance: decubitus and consequential sepsis, urosepsis and pneumonia (Phadke, 1987). Since 
then, other assessments were carried out and found that MS-related CoDs are responsible for 
the death of 47-75% of the patients (Bronnum-Hansen et al., 2004; Leray et al., 2007; Phadke, 
1987; Sadovnick et al., 1991). The other most common causes of death are similar to the 
general first world population, namely cardio- and cerebrovascular diseases (CVD) and 
malignancies (Bronnum-Hansen et al., 2004; Grytten Torkildsen et al., 2008; Phadke, 1987). 
On the contrary, suicide rates are constantly reported to be higher among PwMS as compared 
to the general population (Bronnum-Hansen et al., 2005; Feinstein and Pavisian, 2017; 
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Fredrikson et al., 2003). 
The first data concerning the lifespan of the patients arose from Denmark in 2004 (Bronnum-
Hansen et al., 2004). It was the result of a 40-years follow-up assessment from the Danish MS 
registry. It found, that PwMS live approximately 10 years shorter, than their life expectancy at 
birth(Bronnum-Hansen et al., 2004). Other evaluations carried out in North America and 
North-Europe found this loss of years to be 6-12.8 years (Hader, 2010; Kingwell et al., 2012). 
MS holds a great mortality risk for the patients beyond the reduced life expectancy. Several 
evaluations has shown that PwMS have an about three-fold mortality risk as compared to the 
general population (Sumelahti et al., 2010). Patients with the primary progressive (PPMS) 
form have been shown to have a higher risk as compared to the initially relapsing forms 
(Grytten Torkildsen et al., 2008; Kingwell et al., 2012). Patients, in whom MS manifested 
before the age of 18, have a four-fold risk of dying, which is similar to the mortality risk of 
type II diabetes mellitus and higher than some common malignancies diagnosed in the early 
phases (de Marco et al., 1999; Hooning et al., 2006; Sumelahti et al., 2010). Some evaluations 
found that women have a slightly higher relative risk of dying than man, but those results are 
somewhat controversial (Bronnum-Hansen et al., 2004; Kingwell et al., 2012; Sumelahti et 
al., 2010).  
 
I.3. Natural history of MS 
The two main clinical attributes of the disease can be specified as the activity and the 
progression of the disease. Activity can be described as the acute onset of new neurological 
symptoms that end up partially or completely remised (relapse) or – as a newer concept - new 
or enlarging, potentially contrast-enhancing lesions on the MRI scan (Lublin et al., 2014). 
Progression is the phenomena that describes the steady, yet irreversible worsening of 
symptoms and signs of MS over 6 months or more (Lublin et al., 2014). Based on these 
attributes, several clinical courses of the disease were defined by Lublin and colleagues in 
1996 (Lublin and Reingold, 1996). The most common form is the relapsing-remitting 
(RRMS) form, which is characterized by the above described relapsing, remitting periods 
(Lublin and Reingold, 1996). After a time, a large proportion of these patients convert into the 
secondary progressive (SPMS) phase, which is characterized by steady progression instead of 
relapses (Lublin and Reingold, 1996). About 10-15% of the patients never experience the 
relapsing phase, and the disease is defined by steady progression from the beginning, thus it is 
called PPMS (Lublin and Reingold, 1996). A small proportion of patients experience this 
progressive phase at the same time with relapsing phase, this course was labelled relapsing-
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progressive MS (RPMS) (Lublin and Reingold, 1996). Also, a so-called benign course of the 
disease was described, where patients do not exhibit meaningful activity or progression after 
the initial attack, meaning that during a period of fifteen years, the patients’ Expanded 
Disability Status Scale (EDSS) score did not exceed 3 points and they rarely suffered relapses 
(Lublin and Reingold, 1996).  
However, this type of clinical phenotypisation needed to be revised as our knowledge of MS 
expanded. New clinical courses had to be defined based on the new information and the found 
link between clinical characteristics and paraclinical investigations. In 2014, Lublin and 
colleagues published a revision of the originally defined phenotypes and introduced new 
aspects of MS as well (Lublin et al., 2014). As a new concept, clinically isolated syndrome 
(CIS) was introduced: CIS is now recognized as the first clinical presentation of a disease that 
shows characteristics of inflammatory demyelination that could be MS, but has yet to fulfil 
criteria of dissemination in time (Lublin et al., 2014). As for the classical clinical courses, a 
new concept was developed, with activity and progression incorporated into the definitions. 
Now we recognize two initial subtypes of MS: relapsing and progressing subtypes (Lublin et 
al., 2014). Relapsing MS can be either RRMS, which can be active or not active, and CIS can 
also be not active or active, in which case it fulfils the diagnostic criteria for dissemination in 
time and space, it means conversion to RRMS (Lublin et al., 2014). Progressive patients can 
be PPMS patients, with progressive accumulation of disability from the onset, or SPMS 
patients with progressive accumulation of disability after an initial relapsing phase (Lublin et 
al., 2014). Progressive patients can be either active and progressing, active but non-
progressing, non-active but with progression and non-active and non-progressing (Lublin et 
al., 2014). The benign term was excluded as a disease course indicator per se, as new data 
arose from several studies describing the natural history of the disease (Lublin et al., 2014). 
Ebers and colleagues have shown, that the initial phase of the disease – defined by reaching 
the milestone of EDSS score 3 points, the threshold for the beginning of irreversible neuronal 
damage – show a grand variation in time (Ebers, 2001). Patients with higher initial activity 
and severity of progression will reach this threshold earlier (Ebers, 2001). But from EDSS 3 
points, to EDSS 6 points, this variation disappears, meaning that after reaching the first signs 
of irreversible neuronal damage, the gradual worsening of the patients goes down in the same 
manner (Ebers, 2001). Thus despite a patient appearing to have the benign course in the 15 
years, when followed-up after the initial years, will still reach EDSS score 6 points with the 
same speed as the other patients do. This was an important reason (among others) that 
initialized the search for other signs and symptoms of MS that may not be incorporated into 
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the EDSS system but can be prevalent during the first, seemingly inactive phase of the 
disease. Evaluations discovered that among benign patients, fatigue is as prevalent, as in other 
courses; that approximately 50% of these patients exhibit signs of cognitive dysfunction; that 
a grand proportion of “benign” patients are burdened by depression, anxiety or other 
psychiatric conditions, which are not yet routinely examined and followed-up (Amato et al., 
2006a; Correale et al., 2012; Sayao et al., 2007; Ton et al., 2017). These information may 
propose, that the activity in this group seems low because the disease does not manifest in the 
somatic symptoms of MS, yet in the psychopathological domains. 
 
I.4. Psychopathological symptoms of MS 
Aside from the somatic manifestations of the disease, there are several other symptoms 
burdening MS patients which are psychological in nature and therefore much harder to 
recognize or to measure. These symptoms are cognitive impairment (CI), depression, fatigue 
and anxiety. 
 
I.4.1. Cognitive impairment in MS 
Classically, cognition was believed to remain largely intact through the course of the disease. 
Original descriptions of the disease counted moria and euphoria among the cognitive 
symptoms, which only appear at the very end of the disease (Charcot and Harris, 1991). 
In heavy contrast to this, in the recent two decades, data emerged showing that CI is a very 
common and heavily debilitating symptom of MS. Its prevalence was shown to be 43-70% by 
different evaluations (Chiaravalloti and DeLuca, 2008). It seriously worsens the QoL of the 
patients in almost all aspect of life. MS patients with CI have reduced physical independence 
and competence in daily activities, such as claiming their ability for safe driving (Goverover 
et al., 2007; Marcotte et al., 2008; Rao et al., 1991b). These patients report impaired social 
lives and higher rates of divorce as compared to cognitively healthy patients (DeLuca et al., 
2015). Also it reduces the patients’ coping mechanism, medical adherence and rehabilitation 
potential thus negatively impacting medical management (Bruce et al., 2010; Ehrensperger et 
al., 2008; Langdon and Thompson, 1999). In some assessments, CI is indicated to be the 
strongest predictor of MS patients’ becoming unemployed (Honarmand et al., 2011; Morrow 
et al., 2009). 
Importantly, cognitive dysfunction is not global among PwMS (rarely can it be described as 
dementia) (Langdon, 2011). There are several cognitive domains that are – to various degree - 
characteristically affected by the disease including attention, information processing 
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efficiency, executive functioning, short-term and long-term memory (Langdon, 2011). Of 
these, information processing speed, visual and verbal memory seems to be the most 
vulnerable (Langdon, 2011).  
Cognitive dysfunction can appear at any stage of the disease. It was found that it can begin 
very early in patients with CIS and also a small but substantial portion of patients with 
radiologically isolated syndrome (RIS) showed signs of CI (Amato et al., 2012a; Glanz et al., 
2007). It was also found that CI can manifest as an acute relapse of the disease (Morrow et al., 
2011). There is evidence showing that MS may primarily present with cognitive (and 
pathophysiological) symptoms with minimal or no other neurological systems involved 
(Calabrese et al., 2015). It was reported, that sadly, once CI appears, there is a very small 
chance for any improvement (DeLuca et al., 2015). There were very sparse data on the 
possible predictive factors for developing or the worsening of CI: only recently an Italian 
assessment found that man are more susceptible to CI, and there were some minimal data 
showing that people with higher EDSS scores are more prone to cognitive dysfunction 
(DeLuca et al., 2015; Patti et al., 2015).  
The only real biomarkers for CI in MS are magnetic resonance imaging (MRI) parameters. 
Global brain atrophy, and regional atrophy of the thalamus, hippocampi, frontal cortex and 
basal ganglia show good correlation with CI (Brass et al., 2006; DeLuca et al., 2015; 
Houtchens et al., 2007; Koenig et al., 2014; Morgen et al., 2006). The enlargement of white-
matter lesions in the corpus callosum and the appearance of grey-matter lesions are linked to 
CI (Diker et al., 2016; Rossi et al., 2012). Some recent studies found connection with the 
dysfunction normal-appearing white matter or the default mode networks with cognitive 
decline in MS (Bonavita et al., 2011; Rocca et al., 2010). 
 
I.4.1.1. Measurement of cognitive impairment in MS 
Measuring CI is usually not a routine task of neurologists. It is done by assigning different 
questionnaires designed to measure one (or more) specific cognitive domain to the patient. 
Yet, different diseases tend to affect different domains, hence the tests used should be directed 
towards the domains usually affected by the disease. As noted above, in MS, various cognitive 
functions may decline due to the disease.  
Therefore during the past decades, several composite batteries were created for a deeper 
measurement of CI. Of these, the two most frequently utilized are Rao’s Brief Repeatable 
Battery (R-BRB) and the Minimal Assessment of Cognitive Functions in Multiple Sclerosis 
(MACFIMS) (Benedict et al., 2006; Rao et al., 1991a). 
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Both batteries include longer assessments (5 and 7) that measure the most commonly 
declining cognitive domains in MS. Both batteries include the Symbol Digit Modalities Test 
(SDMT), the Paced Auditory Serial Addition Test (PASAT) and the Controlled Oral Word 
Association Test (COWAT) for the measurement a visual and auditory processing speed and 
language (Rao et al., 1991a). Other than these, R-BRB utilizes the 10/36 Spatial Recall Test 
(10/36) for visual memory and the Selective Reminding Test (SRT) for verbal memory (Rao 
et al., 1991a). In the MACFIMS, visual memory is measured by the Brief Visuospatial 
Memory Test Revised (BVMT-R) and verbal memory is assessed by the California Verbal 
Learning Test Second Edition (CVLT-II) (Benedict et al., 2006). The MACFIMS also 
included the Judgment of Line Orientation (JLO) for evaluating the spatial processing and the 
Delis-Kaplan Executive Function System (DKEFS) for higher executive functions (Benedict 
et al., 2006). Both batteries have been validated to several language and have been used 
efficiently for the measurement of CI.  
However, there are limitations for the usefulness of such batteries in clinical practice. Both 
test require long time for administration (45 and 90 minutes) which clinical practitioners don’t 
have in the outpatient units. Furthermore, some of these tests require special equipment also 
not routinely available in clinical settings. Last but not least, the administration of these 
batteries require a neuropsychologist, thus making the routine administration of these batteries 
all but impossible. For these reasons, the need for the creation of a well-composed but simple 
screening tool arose that could be applied to routine use, requires no special personnel or tool 
yet still sensitively measures CI in MS. 
 
I.4.1.2. The Brief International Cognitive Assessment for Multiple Sclerosis  
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery was 
created in 2011 by a panel of neurologists and neuropsychologists (Langdon et al., 2012). 
They aimed to develop a sensitive screening tool for CI in MS. They agreed on the following 
consensus criteria that the battery should conform to in order to be useful (Langdon et al., 
2012): 
1. Administration should not require more than 15 minutes. 
2. It should not require any special personnel, tool or training. 
3. The battery should be able to be administered easily in the clinical setting. 
4. It should measure the most frequently affected cognitive domains in MS: information 
processing speed, visual memory and verbal memory. 
After the thorough and careful review of the international literature, they identified six 
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eligible questionnaires that met these criteria: two for each cognitive domains. After that, they 
developed a scoring system for both psychometric values and clinical applicability and the 
members of the panel rated all sex tests. Based on these ratings, they chose three 
questionnaires that now comprise BICAMS: the SDMT, the first three immediate recall trials 
of the BVMT-R and the first five immediate recall trials of CVLT-II (Langdon et al., 2012). 
 
1. The SDMT is the measure of the information processing speed. It is given to the 
participant as a sheet of paper containing nine symbols in pseudo-randomized lines. 
All symbols are paired with a number in a key at the top of the sheet. During the 
assessment, the patient first undergoes a short practice of 10 symbols. After, they have 
to pair as many of the symbols with the numbers as they can in 90 seconds. Both a 
written and an oral version of the test exist: with the written version, the patients have 
to write the correct digits on the paper, whereas in the oral version the patient is 
required to say the correct number out loudly while the administrator notes them. The 
dependent variable is the total number of correct responses (Smith, 1982). 
2. The CVLT-II is a long battery designed for the in depth evaluation of verbal memory. 
BICAMS utilizes only the first five immediate recall trials of CVLT-II, which is 
comprised of a list of 16 words in 4 semantic categories. During administration, the 
examiner reads the list aloud at the approximate speed of 1 word/second. After, the 
patients have to recall as many of the words as they can and repeat them back to the 
administrator. The order is arbitrary and there is no time limit for the assessment. The 
dependent variable is the total number of correct words recalled during the five trials 
(Delis, 2000). 
3. The BVMT-R is also a longer questionnaire designed for measuring the visual 
memory of the patients. BICAMS utilizes only the first three immediate recall trials. 
When administrating the test, the patients are given a blank sheet of paper divided into 
six equal parts and a pencil or a pen. Then the administrator shows them a matrix of 6 
abstract designs for a learning period of 10 seconds. After, the patients are required to 
reproduce those on the blank paper as accurately as they can. Each design receives a 
score of 0, 1, or 2 based on accuracy and the location. There is no time limit for this 
test and the dependent variable is the total points received for the reproduced designs 
during the three trials (Benedict, 1988). 
The committee recommended that the battery should not be used within 1 month of recovery 
from relapse or within 1 month of steroid therapy, because it can negatively affect memory 
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functions (albeit reversibly) (Langdon et al., 2012). It was also concluded that the evaluations 
should be conducted annually or bi-annually (Langdon et al., 2012). 
I.4.2. Depression 
The aetiology of depression and mood disorders – not unlike in other disorders – are 
multifactorial. Thorough investigations aimed to determine the biological, psychological and 
social factors of developing depression in MS.  
It seems, that genetic factors do not play a significant role in the association of MS and 
depression as family history do not seem to increase the risk (Joffe et al., 1987; Johansson et 
al., 2014). MRI studies however have shown, that frontal and temporal lobe atrophy and 
lesion volume correlate with the appearance of depression in PwMS (Feinstein et al., 2014). 
Some new data point toward the importance of inflammatory processes in the development of 
depressive symptoms (Patten et al., 2017). The earliest DMTs (the beta-interferons [IFN-β]) 
have been associated with inducing depression-like symptoms or episodes in treated patients 
(Patten et al., 2017). Yet, as was expected, evaluations committed to the assessment of 
psychosocial variables (such as how MS affects young patients’ interpersonal relations and 
career leading to various sorts of  stressors) found, that these are very important contributors 
to the development of depressive symptoms in PwMS (Beal et al., 2007). 
However the aetiology might be, nonetheless, depression remains a frequent problem among 
MS patients. Epidemiological surveys differ greatly on its prevalence, with a reported pooled 
rate of 30.5%, but these differences could be traced back to the different methodologies of 
evaluation (Boeschoten et al., 2017). Assessments that identified depression with structured 
interviews or by a clinical examination as a depressive disorder, yielded lower rates, with a 
pooled prevalence of 20.6% and a range of 1.3-44.1% (Boeschoten et al., 2017). Yet other 
studies, which utilized depression rating-scales and identified patients by a cut-off point with 
clinically relevant depressive symptoms, resulted in the pooled prevalence of 35.0% with a 
range of 9.3-76.2% (Boeschoten et al., 2017).  
Depression is a serious burden to PwMS. It heavily worsens the patients QoL in virtually all 
levels: it was found to be a contributor to health-related QoL almost as strong as physical 
disability itself by several evaluations (Berrigan et al., 2016; Carta et al., 2014). It can lower 
the adherence to medical treatment, and potentially aggravate other symptoms, such as 
fatigue, pain or anxiety, multiplying their impact on QoL (Feinstein et al., 2014). It is also 
known, that depression can cause pseudo-dementia, or worsen the already existing cognitive 
disabilities again possibly aggravating its impact on PwMS (Feinstein et al., 2014). 
Importantly, it was established as well, that the risk of suicide is much higher in MS than in 
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the general population, and the link between depression and suicide is strong and well-
understood (Bronnum-Hansen et al., 2005).   
As was mentioned above, the evaluation of depression can be done following multiple 
directions. Yet, during the three-monthly visits of the patients in the outpatient units, screening 
tools are the most useful, as they are reliable, yet easily administered and scored and they 
sensitively reveal clinically relevant depressive symptoms. Many of these tools are self-filling 
questionnaires, as they are the least time-consuming but still very effective. One of the most 
frequently utilized such questionnaire is the Beck’s Depression Inventory (BDI-II) (Beck, 
1996).  
BDI-II consists of 21 items, all are related to an aspect of depression and all contain four 
possible choices of response ranging in intensity. Every response can be scored from 0 to 3 
points, with 3 being the most intense answer (Beck, 1996). The maximum achieved score can 
be 63 points (Beck, 1996). The cut of is 13 points; any patient reaching 13 or more points can 
be regarded to have clinically relevant depressive symptoms (Beck, 1996). 
 
I.4.3. Fatigue 
Though fatigue is a common word, the medical definition of it as a pathological symptom 
cannot be given easily. It is described as a complex symptom defined by three underlying 
components: 1. asthenia/daytime tiredness, 2. pathological exhaustibility and 3. worsening of 
symptoms due to stress (Iriarte et al., 2000).  
In light of MS, fatigue can be either primary or secondary. Primary fatigue is caused by the 
pathophysiology of the disease itself: loss of connectivity between cortical and subcortical 
structures due to lesion burden; mediators released due to immune-mediated inflammation; 
and neuroendocrine dysfunctions due to damage in the central regulatory regions of the CNS 
(Patejdl et al., 2016). Secondary fatigue is related to other symptoms of MS, pain, 
comorbidity or side-effect of DMTs (Patejdl et al., 2016). Importantly, secondary fatigue can 
accompany primary fatigue and worsen its effect.  
Fatigue frequently appears as the initial symptom of the disease before any other measureable, 
easily evaluated signs of the disease appear (Kister et al., 2013; Runia et al., 2015).  It can be 
easily over-looked or “brushed-away” as simple tiredness or lack of motivation, which is a 
grand problem, because fatigue is the most common symptom of MS. Its prevalence was 
measured up to 95%, thus it appears at some point in effectively every MS patient’s life 
(Kister et al., 2013). Furthermore, the majority of the patients report it to be one of the worst, 
while a sizeable proportion (15%) to be the worst symptom of the disease (Fisk et al., 1994a). 
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Thus, this symptom has a profound negative effect on the patients’ perceived QoL 
independently from physical disability, disease duration, disease course or other social or 
clinical parameters (Benedict et al., 2005). Interestingly however, despite it can hypothetically 
affect cognitive functions, no strong connection has been found to date (Morrow et al., 2009).  
Because of its nature, fatigue is hard to measure and to objectify. No gold-standard exist for 
its evaluation, and to date, it is based on self-reported questionnaires, such as the Fatigue 
Impact Scale (FIS) (Fisk et al., 1994b). The FIS battery comprises of 40 questions, divided 
into 3 subscales: 20 questions about the social aspects of fatigue, 10 questions about the 
physical and 10 questions about the cognitive aspects (Fisk et al., 1994b). The answers are 
scored from 0 (minimal degree) to 4 (severe degree) points, 160 points in total (Fisk et al., 
1994b). The cut-off can vary, but it is usually given at ≥40 points (Losonczi et al., 2011). 
 
II. Aims 
 
Our aims with the reported evaluations were to: 
1. Determine the causes of death, the standardized mortality ratios (SMR) and the survival 
times from disease onset among the Hungarian MS patients with any possible difference 
between the sexes or the different clinical courses of the disease from January 1st 1993 to 
January 1st 2013. 
2. Validate the BICAMS battery to Hungarian language. 
3. Assess any possible connection between cognitive performance and fatigue. 
4. Determine the prevalence of CI among Hungarian RRMS and CIS patients. 
5. Determine the possible differences in regard to CI between sexes and patients with 
different educational levels. 
6. Find any possible risk factors for developing CI among RRMS and CIS patients in 
Hungary. 
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III.  Patients and methods 
 
III.1. Mortality and causes of death among Hungarian MS patients 
 
III.1.1. Patients 
The MS outpatient’s clinic of the Department of Neurology of the University of Szeged is 
responsible for the health care of all MS patients from Csongrád- (population: 419.366) and 
parts of Bács-Kiskun- (population: 522.312) and Békés- (population: 357.740) counties (total 
number of the population the unit is responsible for is approximately 900.000 people) in the 
southern region of Hungary (Hungarian Central Statistical Office). All MS patients were 
included into the Multiple Sclerosis Register of the Department of Neurology of the 
University of Szeged since 1993 (Bencsik et al., 2017).  
In the assessed 20 years, 740 MS patients were treated for MS at our centre, with a total 
follow-up person years of 10303 years. Two-hundred and four were men (27.5%, 2806 person 
years), 536 were women (72.5%, 7497 person years). The F/M ratio was 2.63:1. Six-hundred 
and eighty-eight patients had RR or SP disease course (93%, 9733 person years) and 52 
patients PPMS (7%, 570 person years). During the period of our evaluation, 121 patients 
(16%) died, 46 men and 75 women: 23 suffered from PPMS, 98 from RR/SPMS. Forty 
patients (33%) received DMTs (IFN-β, glatiramer-acetate [GA] or mitoxantrone), the mean 
duration of treatment was 6.2 (95% CI: 5.1-7.3) years, and the EDSS score at the beginning of 
the treatment was 3.3 (95% CI: 2.5-4.0). 
 
III.1.2. Methods 
The socio-demographic data such as the sex, the date of birth, the date of MS onset, the 
course of the disease and the date of death of the patients were obtained from our Register. 
Between 1993 and 2001, the diagnosis was based on the Poser diagnostic criteria, after 2001, 
the McDonald diagnostic criteria were used (McDonald et al., 2001; Poser et al., 1983). The 
different courses of MS were determined per the Lublin-criteria from 1996 (Lublin and 
Reingold, 1996). 
The CoD was determined from the pathological records (in case of 53 patients) or the medical 
certificates of the cause of death provided by the families (in case of 68 of the patients). Data 
on the number of deaths and the CoDs in the Hungarian general population distributed by sex, 
age and calendar year were derived from the website of the Hungarian Central Statistical 
Office. The SMRs were calculated: it is the ratio of the observed to the expected numbers of 
deaths (Andersen and Vaeth, 1989). The expected numbers of deaths were calculated by 
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multiplying the age-, sex- and time-specific person-years of observation by the respective age-
, sex- and time-specific population death rate (Andersen and Vaeth, 1989). SMRs and 95% 
confidence intervals (95%CI) were calculated with the assumption that the numbers of deaths 
followed a Poisson distribution. For the analysis of survival time from MS onset of the sexes 
and patients with different clinical courses, Gehan-Breslow test was utilized.  
The study was approved by the Human Investigation Review Board of the University of 
Szeged (approval number 3267) in accordance with the Helsinki Declaration. 
 
III.2. The Hungarian validation of the BICAMS battery 
 
III.2.1. Patients and healthy control group 
Sixty-five patients treated at the MS Outpatient’s Unit of the Department of Neurology of the 
University of Szeged and 65 healthy controls (HC) matched in age, sex and years of education 
were recruited. Sixteen were men, 49 women; 31 members of both groups studied ≤12 years, 
and 34 of them studied for at least 13 years. All sociodemographic data on the patients 
including age, age at disease onset, disease duration and EDSS score were obtained from the 
Multiple Sclerosis Register of Szeged (Bencsik et al., 2017). Among the patients there was no 
pre-selection applied for CI.  
Inclusion criteria were: 
A. Age between 18-65 years.  
B. First language is Hungarian. 
C. RRMS patients.  
D. All patients were in remission during the evaluation. 
E. EDSS score 0-6.5.  
Exclusion criteria were: 
A. CIS, SPMS or PPMS for homogeneity of the population. 
B. Patients undergoing acute infection or an acute relapse.  
C. Diagnosed psychiatric, mood or personality disorder among both groups as they can 
cause CI. 
D. History of chronic alcohol or drug abuse among both groups as they can also cause CI. 
 
III.2.2. Methods 
The validation was conducted per the international standards given in 2012 (Benedict et al., 
2012). 
1. The CVLT-II list of words were translated and retranslated from English to Hungarian and 
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vice versa respectively (the other two tests did not require translation due to their nature).  
2. The relevant parts of the tests manuals were translated into Hungarian.  
3. The initial testing, and after 3 weeks, the retesting of the participants between December 
2013 and March 2014. In our evaluation, we used both the oral and the written version of 
SDMT. Also for the assessment of the correlations between the cognitive state and fatigue, all 
65 patients had completed the Hungarian version of the FIS (Losonczi et al., 2011). For the 
evaluation of connection with FIS, we used the first BICAMS tests of the patients. 
Paired sample T-tests were utilized for the measurement of differences between the patients 
and the HC group. The test-retest reliability and the correlation between BICAMS and FIS 
were assessed by Pearson correlation coefficients. To analyse the difference between the test 
and retest performances, two-way repeated measures ANOVA with the result of the BICAMS 
battery being a composite outcome was utilized, and one-way repeated measures ANOVA to 
assess the differences by the battery-types that compose the BICAMS battery. For the 
statistical analysis, SPSS 21.0 software was used. 
Informed consent was obtained from all individual participants included in the study. The 
study was authorized by the Ethics Committee of the University of Szeged (authorization 
number 127/2013). 
 
III.3. The prevalence of cognitive impairment and its risk factors among Hungarian 
RRMS and CIS patients 
 
III.3.1. Patients 
The study was conducted between February 2014 and November 2015. In total, 553 (28 CIS 
and 525 RRMS) patients were enrolled from three Hungarian MS centres. Four-hundred and 
four from the MS outpatients’ clinic of the Department of Neurology of the University of 
Szeged; 111 from the MS outpatients’ clinic of the Jahn Ferenc Dél-Pest Hospital in Budapest 
and 38 from the MS outpatients’ clinic of the Markhot Ferenc Hospital in Eger.  
One-hundred and fifty-seven patients were man, 396 women, classified into 3 categories 
depending on their educational level: 123 patients in the first group with less than 12 years of 
education, indicating they did not obtain a high school degree; the second group, 209 patients 
for the second group whom either finished high school or after high school obtained some 
qualification but not a degree from college or university (12-15 years of education); and 221 
patients for the third group whom obtained college or university level of graduation (16 or 
more years of education). Additionally, all the patients currently enrolled to college or 
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university were placed in the third group. Regarding the therapy, 90 patients received no 
DMTs; 169 patients received IFN-β, 129 patients GA, 31 patients teriflunomide, 33 patients 
dimethyl-fumarate therapy; 56 patients were on natalizumab, and 41 patients on fingolimod. 
Additionally, 1 patient was involved in the daclizumab, 1 in the LINGO-1 and 1 in the 
siponimod clinical trials. 
All sociodemographic data on the patients including age, age at disease onset, disease 
duration and EDSS score were obtained from the Multiple Sclerosis Register in case of the 
centre of Szeged, or from the outpatient treatment reports from the other centres (Bencsik et 
al., 2017).  
The inclusion and exclusion criteria were the same as in the aforementioned BICAMS 
validation study, with the exception of the inclusion of CIS patients. 
 
III.3.2. Methods 
We evaluated the patients’ cognitive state with the Hungarian version of the BICAMS battery 
(Sandi et al., 2015). As no consensual threshold on CI for BICAMS has been proposed yet, 
we used the thresholds given in the manuals of the separate tests (-1.5 standard deviation [SD] 
below the average for SDMT; T-score 40 or below for BVMT-R and CVLT-II) (Benedict, 
1988; Delis, 2000; Smith, 1982). We identified patients with CI, whom had abnormal scores 
on one or more tests, a criterion proposed by Dusankova et al. in 2012 in their own BICAMS 
validation process(Dusankova et al., 2012). The BDI-II was utilized to assess depression: all 
patients with a score of 13 or above were classified as depressed (Beck, 1996).  
To determine the predictors of CI, a univariate logistic regression model was used. For the 
evaluation of the differences in CI and depression between the sexes and patients with 
different levels of education, Fisher’s exact test and chi-square tests were used. To assess the 
differences between key clinical and demographic factors (age, age at disease onset, disease 
duration, EDSS score) one-way ANOVA was utilized.  
Informed consent was obtained from all individual participants included in the study. The 
study was approved by the Human Investigation Review Board of the University of Szeged in 
accordance with the Helsinki Declaration (authorization number 127/2013). 
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IV. Results 
 
IV.1. Mortality and causes of death among Hungarian MS patients 
The demographic data of our patients sorted by sex and the course of the disease are presented 
in Table 1.  The mean age at death was 54.2 (95%CI: 52.0-56.5) years in the whole cohort, 
and the mean final EDSS score was 6.5 (95%CI: 6.1-6.9) points. 
 
Table 1: Demographic data of the deceased patients by sex and clinical course 
  
Total 
(N=121) 
Sex Clinical course 
Men 
(N=46) 
Women 
(N=75) 
RR/SP 
(N=98) 
PP 
(N=23) 
Mean age at 
death (95%CI) 
[years] 
54.2  
(52.0-56.5) 
53.3  
(52.0-56.6) 
54.8  
(49.9-57.2) 
53.5  
(50.9-56.0) 
57.5  
(53.3-61.8) 
Final EDSS 
(95%CI) [points] 
6.5  
(6.1-6.9) 
6.5  
(6.0-7.1) 
6.5  
(6.0-7.0) 
6.2  
(5.7-6.7) 
7.4  
(6.8-8.1) 
95%CI, 95% confidence interval; EDSS, Expanded Disability Status Scale; RR, 
relapsing-remitting; SP, secondary progressive, PP, primary progressive 
 
IV.1.1. Causes of death 
Seventy seven (63.6%) of the 121 patients died due to MS-related causes, which were the 
effects of long-term disability such as bronchopneumonia, sepsis and infection of the 
urogenital tract (ICD10: G35, A00-B99, J00-J99). In the other 44 cases (36.4%), CoDs were 
categorized as CVD (stroke, acute myocardial infarct and aortic rupture, [ICD10: I20-I25, 
I60-I69, I71]), malignant tumours (ICD10: C00-D09), suicide (ICD10: X71-83) and other 
causes (hepatic failure, pulmonary emboli, [ICD10: K70-77, I26-I41]). CVD was the CoD of 
16 patients (13.2%), malignant tumours in 14 cases (11.6%), 4 people committed suicide 
(3.3%) and 10 patients (8.3%) died of the causes labelled “other” above (Figure 1). For 
comparison, CVD are responsible for 35.6%, malignancies for 28.0%, suicide for 1.5%, 
hepatic failure and pulmonary emboli for 8.1% and the causes labelled as “MS-related” for 
the 6.0% of deaths in the Hungarian general population. 
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Figure 1: The causes of death in the Hungarian MS population by percentage 
 
MS, multiple sclerosis; CVD, cardio-and cerebrovascular diseases. 
IV.1.2. Mortality risk 
During the observed 20 years, 121 patients died, while the expected number of deaths based 
on the data from the general population was 47.93; the SMR was 2.52 (95%CI: 2.10-3.01) 
(Table 2). The SMR for MS-related CoDs was 105.34 (95%CI: 83.13-131.60), while SMRs 
for other causes were all below or approximately 1.00 (Table 2).  
Table 2: Mortality risk in Hungarian MS patients 
Causes of 
death Expected number of death 
Observed number of 
death SMR (95%CI) 
All causes 47.93 121.00 2.52 (2.10-3.01) 
MS-related 0.73 77.00 105.34 (83.13-131.60) 
CVD 18.98 16.00 0.84 (0.50-1.34) 
Malignancies 17.78 14.00 0.79 (0.45-1.29) 
Suicide 3.89 4.00 1.03 (0.33-2.48) 
Other 6.55 10.00 1.53 (0.78-2.72) 
SMR, standardized mortality rate, CVD, cardio- andcerebrovascular diseases 
There was virtually no difference between the sexes: the SMR for men was 2.46 (95%CI: 
1.82-3.25) and the SMR for women was 2.57 (95%CI: 2.03-3.20) regarding all CoDs. The 
SMR for MS-related causes were the highest in both sexes, but it was markedly lower in men 
63,6% 
13,2% 
11,6% 
3,3% 
8,3% 
MS-related 
CVD 
Malignant tumors 
Suicide 
Other 
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than women (Table 3). SMRs were virtually the same regarding CVDs, malignant tumors and 
suicide, yet men had a double risk of dying caused by hepatic failure or pulmonary emboli 
(Table 3).  
Table 3: Mortality risk in Hungarian MS patients by sexes 
  Men Women 
Causes of 
death 
Expected 
number of 
death 
Observed 
number 
of death 
SMR (95%CI) 
Expected 
number of 
death 
Observed 
number 
of death 
SMR (95%CI) 
All causes 18.71 46.00 2.46 (1.82-3.25) 29.22 75.00 2.57 (2.03-3.20) 
MS-related 0.29 25.00 86.23 (57.03-125.40) 0.44 52.00 117.91 (88.97-153.40) 
CVD 6.70 6.00 0.90 (0.36-1.86) 12.28 10.00 0.81 (0.41-1.45) 
Malignant 
tumor 6.71 7.00 1.04 (0.46-2.06) 11.07 7.00 0.63 (0.28-1.25) 
Suicide 2.02 2.00 0.99 (0.17-3.27) 1.87 2.00 1.07 (0.18-3.54) 
Other 2.98 7.00 2.01 (0.82-4.19) 3.57 4.00 1.12 (0.36-2.71) 
SMR, standardized mortality rate; CVD, cardio- and cerebrovascular diseases 
 
Regarding the different clinical courses of MS, the SMR for RR/SPMS patients was 2.34 
(95%CI: 1.91-2.84), while it was much higher, 4.10 (95%CI: 2.66-6.05), in case of patients 
with PPMS. The SMR for MS-related CoDs was almost double in PPMS patients than in the 
RR/SPMS group (Table 4). PPMS patients’ survival risk associated with CVDs was higher 
than in RR/SPMS patients (Table 4). No PPMS patient committed suicide, while the survival 
risk associated with hepatic failure and pulmonary emboli was almost six-fold (SMR: 5.78) 
than in the RR/SPMS group (Table 4).  
Table 4: Mortality risk in Hungarian MS patients by clinical courses 
  RR/SPMS PPMS 
Causes of 
death 
Expected 
number 
of death 
Observed 
number 
of death 
SMR (95%CI) 
Expected 
number 
of death 
Observed 
number 
of death 
SMR (95%CI) 
All causes 41.90 98.00 2.34 (1.91-2.84) 5.62 23.00 4.10 (2.66-6.05) 
MS-related 0.64 62.00 96.42 (74.56-122.80) 0.09 15.00 170.50 (99.05-274.80) 
CVD 16.24 12.00 0.74 (0.40-1.26) 2.65 4.00 1.51 (0.48-3.67) 
Malignant 
tumor 15.73 12.00 0.76 (0.41-1.30) 2.09 2.00 0.96 (0.16-3.16) 
Suicide 3.49 4.00 1.15 (0.36-2.75) 0.44 0.00 0.00 (-) 
Other 5.80 8.00 1.38 (0.64-2.62) 0.35 2.00 5.78 (0.97-19.10) 
RR/SPMS, relapsing-remitting and secondary progressive MS; PPMS, primary progressive 
MS; SMR, standardized mortality rate; CVD, cardio- and cerebrovascular diseases 
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IV.1.3. Survival time 
The median survival time from disease onset was 35 years in case of the whole MS 
population. Regarding the sexes, we found a statistically significant (p<0.001), yet clinically 
not relevant difference: the median survival time from disease onset for women was 35 years, 
while it was 32 years for men (Figure 2). However, the median survival times differed greatly 
between the different clinical courses (p<0.001): PPMS patients’ median survival time from 
disease onset was 14 years, while it was 35 years in the RR/SPMS group (p<0.001) (Figure 
3). 
 
Figure 2: Kaplan-Meier survival curves representing survival from onset of the patients 
by sex, with median survival times and 95% confidence intervals 
 
95%CI, 95% confidence interval 
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Figure 3: Kaplan-Meier survival curves representing survival from onset of the patients 
by disease course, with median survival times and 95% confidence intervals 
 
RR/SPMS, relapsing-remitting and secondary progressive multiple sclerosis; PPMS, 
primary progressive multiple sclerosis; 95%CI, 95% confidence interval 
 
IV.2. The Hungarian validation of the BICAMS battery 
The mean age of the recruited patients was 41.9 (±8.9) years, the mean age at disease onset 
was 29.8 (±9.9) years, the mean disease duration was 11.1 (±7.6) years and the mean EDSS 
score was 2.5 (±1.8) points. The mean age of the HC group was 40.9 (±11.8) years, which is 
not significantly different from the patients group (p=0.610). 
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IV.2.1. Validity of the Hungarian BICAMS battery 
The group data and the differences between the raw scores of the patients and HC group are 
shown in Table 5 during all 4 trials and the retests as well. MS patients performed 
significantly worse in all trials than the members of the HC group (p≤0.001 in all tests other 
than the first CVLT-II; where p=0.017). 
Table 5: Differences between the performance of the patients and the healthy control 
group 
Tests 
Raw score (±SD) 
Significance (p) 
Patients HC group 
SDMT written 44.31 (± 11.76) 54.88 (± 10.32) <0.001 
SDMT written retest 49.38 (± 14.91) 62.31 (± 12.78) <0.001 
BVMT-R 22.54 (± 8.54) 26.68 (± 5.56) 0.001 
BVMT-R retest 26.89 (± 8.21) 31.81 (± 4.13) <0.001 
SDMT oral 55.62 (± 15.48) 66.82 (± 12.44) <0.001 
SDMT oral retest 59.40 (± 18.29) 72.84 (± 13.88) <0.001 
CVLT-II. 55.37 (± 10.71) 59.03 (± 8.29) 0.017 
CVLT-II. retest 61.77 (± 14.20) 70.58 (± 8.29) <0.001 
SD, standard deviation; HC, healthy control; SDMT, Symbol Digit Modalities Test; BVMT-
R, Brief Visuospatial Memory Test Revised; CVLT-II, California Verbal Learning Test 
second edition 
The correlation coefficients between the test and the retest performances are shown in Table 6. 
The overall correlations are very strong (r>0.8, p<0.001 during the SDMT and BVMT-R 
assessments; r=0.678; p<0.001 between the CVLT-II assessments). However, performance of 
the patients shows slightly stronger correlations than the HC group; the greatest difference is 
between the CVLT-II tests (r=0.743; p<0.001 in case of the patients, r=0.453; p<0.001 in case 
of the HC group). 
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Table 6: Correlation coefficients and significance levels 
 Tests 
Overall Patients HC group 
Correlation 
(r) 
Significance 
(p) 
Correlation 
(r) 
Significance 
(p) 
Correlation 
(r) 
Significance 
(p) 
SDMT written 0.874 <0.001 0.883 <0.001 0.796 <0.001 
BVMT-R 0.864 <0.001 0.873 <0.001 0.805 <0.001 
SDMT oral 0.830 <0.001 0.884 <0.001 0.664 <0.001 
CVLT-II 0.678 <0.001 0.743 <0.001 0.453 <0.001 
HC, healthy control; SDMT, Symbol Digit Modalities Test; BVMT-R, Brief Visuospatial 
Memory Test Revised; CVLT-II, California Verbal Learning Test second edition 
The difference between test-retest scores of the patients and HC group was assessed, as we 
observed greater differences in the HC group than between the patients’ scores and found 
weaker test-retest correlation within the HC group. A significant difference was found 
between the test-retest performances the patients and the HC group with a multivariate test 
where the result of the BICAMS battery was the single composite outcome (p=0.020, 
observed power=0.790). With multiple univariate analyses sorted by battery types, there was 
significant difference only in the CVLT-II performances (p=0.003, Table 7). This model 
satisfied the assumption of sphericity (p>0.05).  
Table 7: Univariate tests of the test-retest performances between the patients and 
healthy controls 
Within subject effects Measure p Observed Power 
Test-Retest and Patients-
HC group 
SDMT written 0.063 0.460 
BVMT-R 0.313 0.171 
SDMT oral 0.231 0.223 
CVLT-II 0.003 0.862 
HC, healthy control; SDMT, Symbol Digit Modalities Test; BVMT-R, Brief Visuospatial 
Memory Test Revised; CVLT-II, California Verbal Learning Test second edition. The 
significant difference is highlighted in orange 
IV.2.2. Connection between fatigue and cognitive performance 
We observed significant, albeit moderate negative correlations (r<-0.3; p<0.05) between the 
patients’ overall FIS scores and their cognitive performance in all parts of the BICAMS 
battery (Table 8). Regarding the different dimensions of FIS, the decline in the cognitive 
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correlated best with the physical dimension, then with the social dimension; and in the 
cognitive dimension the only significant correlations were observed with the oral SDMT and 
the CVLT-II results (Table 8). 
Table 8: The correlation coefficients between the raw scores of the BICAMS subtests 
and the dimensions of the FIS questionnaire 
  
Total FIS points Cognitive dimension of 
FIS 
Physical dimension of 
FIS Social dimension of FIS 
Correlatio
n (r) 
Significanc
e (p) 
Correlatio
n (r) 
Significanc
e (p) 
Correlatio
n (r) 
Significanc
e (p) 
Correlatio
n (r) 
Significanc
e (p) 
SDMT 
writte
n 
-0.346 0.008 -0.248 0.052 -0.406 0,001 -0.293 0,023 
BVMT-
R 
-0.322 0.014 -0.247 0.053 -0.351 0,006 -0.255 0,049 
SDMT 
oral 
-0.359 0.006 -0.279 0.028 -0.411 <0,001 -0.239 0,065 
CVLT-
II 
-0.301 0.022 -0.311 0.014 -0.302 0,018  -0.316 0,014 
SDMT, Symbol Digit Modalities Test; CVLT-II., California Verbal Learning Test II.; 
BVMT-R, the Brief Visuospatial Memory Test Revised (BVMT-R). The correlations which 
are not significant are highlighted. 
 
IV.3. The prevalence of cognitive impairment and its risk factors among Hungarian 
RRMS and CIS patients 
 
IV.3.1.  Clinical and demographic data 
We were able to recruit 553 patients for our multi-centered epidemiological study, which 
represent roughly 6.5% of the Hungarian MS population and about 8% of the CIS and RRMS 
patients in the country. All patients filled out the BICAMS battery, while 437 patients BDI-II 
assessment (some the patient did not fully complete the BDI questionnaire hence their score 
could not be reliably calculated or the patient did not consent at all to fill out the 
questionnaire). The mean age of our patients was 44.93±11.69 years, mean age at disease 
onset was 31.95±10.01 years, the mean disease duration was 13.05±8.05 years and the median 
EDSS score 2.0 (IQR: 2.0) points. One-hundred and sixteen patients (26.5%) showed signs of 
depression, but only in case of 17 (4%) patients, this could be categorized as “severe”. 
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In regard of the sexes, we found no significant difference between the rate of patients with 
different educational levels, disease duration, EDSS score and the rate of depression (Table 9). 
Yet men were approximately 4.5 years younger and 3.5 years younger at the onset of MS, 
which are statistically meaningful, yet clinically irrelevant differences (Table 9). 
Table 9: Clinical and demographic data of the male and female participants 
 Male Female Significance (p) 
Age (+SD) 40.83 (±11.35) 45.24 
(±11.49) 
p<0.001 
Age at disease onset (+SD) 29.59 (±9.58) 32.88 
(±9.91) 
p<0.001 
Disease duration (+SD) 12.21 (±8.06) 13.35 
(±8.00) 
p=0.132 
Median EDSS (IQR) 2.0 (2.0) 2.0 (2.0) p=0.436 
Education level <12 years 42 (26.8%) 81 (20.5%) p=0.254 
12-15 years 54 (34.4%) 155 
(39.1%) 
≥16 years 61 (38.9%) 160 
(40.4%) 
Depression Present 31 (23.8%) 85 (27.7%) p=0.477 
Not present 99 (76.2%) 222 
(72.3%) 
SD, Standard deviation. 
 
IV.3.2.  Prevalence of cognitive impairment and its predictors 
Three-hundred and sixteen (57.1%) of our patients had some level of CI: 231 patients (41.7%) 
on the SDMT, 210 patients (38.0%) on the BVMT-R and 75 patients (13.6%) on the CVLT-II 
testing. Ninety-one patients (16.5%) had impaired scores solely on the SDMT, 66 patients 
(11.8%) only on the BVMT-R, and 6 patients (1.1%) only on the CVLT-II assessment. Eighty-
four patients (15.2%) had impaired scores on both the SDMT and the BVMT-R, 9 (1.6%) 
patients on both the SDMT and CVLT-II, and 13 patients (2.4%) on both the BVMT-R and the 
CVLT-II assessments. Forty-seven patients (8.5%) had impaired scores on all three batteries. 
We found no significant difference regarding the clinical and demographic data between the 
patients with CI and those patients without it. Seven (25.0%) of our CIS patients had some 
level of CI as compared to 309 (58.8%) of the RRMS patients, which difference is significant 
(p=0.001). 
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Figure 4: The rate of cognitive impairment in the different subtests of the BICAMS 
battery 
 
SDMT, Symbol Digit Modalities Test; BVMT-R, Brief Visuospatial Memory Test Revised; 
CVLT-II, California Verbal Learning Test 2nd Edition 
A univariate logistic regression analysis was performed to identify any predictors of CI. Of 
the evaluated parameters, only sex, educational level and EDSS score turned out to be 
significant predictors (we dichotomized the EDSS score based on the median EDSS level). 
Men had almost threefold risk to develop CI, the risk of CI was twice as high in patients 
without a high school degree, than people with college and university degree, while patients 
with lower EDSS scores (0-2 points) had approximately half the risk than patients with EDSS 
scores >2 points. 
These predicting factors reflected in the prevalence rates: we found some level of CI in 70.1% 
of the man, while in only 52.0% of the women (p<0.001). Men performed worse on all three 
subtests of the BICAMS battery (SDMT: 55.4% vs. 36.4%, BVMT-R: 48.4% vs. 33.8%, 
CVLT-II: 21.7% vs. 10.4%; p<0.001). The prevalence of CI among patients with <12 years of 
education was 68.3%, among patients with 12-15 years 60.8% and among patients with 16≤ 
years was 48.0% which significantly differed from the other two categories (p=0.001). 
Patients had a significantly higher rate of impaired scores on both the SDMT (53.7%, 41.6%, 
35.3%; p=0.004) and the BVMT-R (48.0%, 39.7%, 30.8%; p=0.006) as the educational levels 
lowered, but there was no significant difference during the CVLT-II testing (17.1%, 14.8%, 
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10.4%; p=0.178). Among patients with EDSS scores between 0-2 points 49.7% had CI, while 
the prevalence was 72.9% among patients with higher EDSS scores (p<0.001) and those 
patients performed worse on all three BICAMS subtests (SDMT: 55.2% vs. 35.4%, BVMT-R: 
53.1% vs. 31.1%, CVLT-II: 20.3% vs. 10.2%; p<0.001). 
When we combined the predictors, and assessed both sexes with logistic regression analysis 
separately, we found that other than their sex, there is no other significant predictor of CI for 
man. The prevalence of CI did not significantly differ in any subgroups based on educational 
levels or EDSS scores, with the sole exception of the BVMT-R performance between men 
with different EDSS scores (Table 10).  
Table 10: The rate of cognitive impairment among man with different educational levels, 
different EDSS scores 
Predictor All 
domain 
p-
value SDMT 
p-
value 
BVMT-
R 
p-
value 
CVLT-
II 
p-
value 
Education 
<12 
years 71.4% 
0.949 
64.3% 
0.227 
47.6% 
0.687 
19.0% 
0.641 12-15 
years 68.5% 57.4% 44.4% 25.9% 
≥16 
years 70.5% 47.5% 52.5% 19.7% 
EDSS 
0-2 
points 66.7% 
0.098 
53.8% 
0.405 
40.9% 
0.012 
19.4% 
0.422 
>2 
points 79.7% 61.0% 62.7% 25.4% 
EDSS, Expanded Disability Status Scale; SDMT, Symbol Digit Modalities Test; BVMT-R, 
Brief Visuospatial Memory Test Revised; CVLT-II, California Verbal Learning Test 2nd 
Edition. The significant difference (p<0.05) is highlighted. 
However educational level and the EDSS score both proved to be a significant predictor of CI 
in woman. Women with 12-15 years of education had an odds ratio (OR) of 1.79 (95%CI: 
1.10-2.92; p=0.021), while women with <12 years of education had an even higher OR of 
2.46 (95%CI: 1.34-4.52; p=0.004) as compared to women with a college or university degree. 
Women with low EDSS scores had an OR of 0.40 (95%CI: 0.24-0.65; p<0.001) as compared 
to women with higher EDSS scores.  
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Table 11: The rate of cognitive impairment among woman with different educational 
levels, different EDSS scores 
Predictor 
All 
domain 
p-value SDMT p-value 
BVMT-
R 
p-value 
CVLT-
II 
p-
value 
Education 
<12 
years 
66.7% 
<0.001 
48.1% 
0.030 
48.1% 
<0.001 
16.0% 
0.083 
12-15 
years 
57.4% 36.1% 38.1% 11.0% 
≥16 
years 
39.4% 30.6% 22.5% 6.9% 
EDSS 
0-2 
points 
42.8% 
<0.001 
27.9% 
<0.001 
27.1% 
<0.001 
6.6% 
0.001 
>2 
points 
69.9% 52.6% 48.9% 18.0% 
EDSS, Expanded Disability Status Scale; SDMT, Symbol Digit Modalities Test; BVMT-R, 
Brief Visuospatial Memory Test Revised; CVLT-II, California Verbal Learning Test 2nd 
Edition. The difference which is not significant is highlighted. 
These differences appeared in the prevalence of CI: the higher the education, the lower the 
prevalence is (66.7% for women with <12 years of education, 57.4% for women with 12-15 
years of education and 39.4% for women with 16≤ years of education; p<0.001); while the 
prevalence of CI is 42.8% among women with low EDSS scores and 69.9% with higher 
EDSS scores (p<0.001; Table 11). Women with higher EDSS performed worse an all three 
BICAMS subtests, while education affected the performance on SDMT and BVMT-R 
assessments, but not on the CVLT-II screening (Table 11). 
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V. Discussion 
 
V.1. Mortality and causes of death among Hungarian MS patients 
 
The data on mortality in MS comes principally from Northern Europe and North-America 
thus leaving “blank spots on the map”. Furthermore, these results show some controversy as 
well. 
The first evaluation regarding CoDs in MS is from 1987, Scotland (Phadke, 1987). It found 
that 62% of the patients died of MS and indicated that CVD and malignancies are the next 
most frequent CoDs(Phadke, 1987). The forthcoming studies resulted in a wider range of MS-
related CoDs up to 75%, but most of them put it between the narrow ranges of 55-62% 
(Bronnum-Hansen et al., 2004; Grytten Torkildsen et al., 2008; Hirst et al., 2008; Koch-
Henriksen et al., 1998; Leray et al., 2007; Redelings et al., 2006; Sadovnick et al., 1991; 
Smestad et al., 2009; Sumelahti et al., 2010). Our study found that 64% of the patients died of 
MS-related causes, which is similar to most of these aforementioned evaluations.  
CVD and malignancies (13% and 11% in our cohort, respectively) are the predominant none 
MS-related CoDs. Previous studies showed discrepancy as they found both lower and higher 
ratios regarding these diseases, but the range is generally between 10-20% similarly to our 
evaluation, and CVD seems to be the more common cause (Bronnum-Hansen et al., 2004; 
Goodin et al., 2012; Phadke, 1987).  
The SMR for all CoDs was 2.52 in our population and this excess overall mortality risk was 
solely due to the excess deaths caused by MS (SMR: 105.34), with CVD and malignant 
tumours posing virtually the same mortality risk than in the general population (SMR: 0.84 
and 0.79 respectively). Earlier studies showed controversy in this (Bronnum-Hansen et al., 
2004; Grytten Torkildsen et al., 2008; Sumelahti et al., 2002). Yet we know, that the incidence 
of these diseases rise with the age of the patients and these are the leading CoDs among the 
elderly population. The mean age at death in our cohort was 54.2 years, so we conclude, that 
the majority of our patients most likely died before these diseases manifested or progressed to 
late phases. The majority of previous assessments found that the risk of suicide is higher 
among MS patients than in the general population (Bronnum-Hansen et al., 2005; Fredrikson 
et al., 2003). Interestingly, this was not the case in Hungary, as the risk of suicide was the 
same as in the general population (SMR: 1.03). A possible reason behind this is the sad fact, 
that Hungary is one of the leading countries in rate of suicide among the developed countries, 
just like Finland, where the mortality risk posed by suicide also did not differ from the general 
population (Sumelahti et al., 2010). 
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We found virtually no difference between the sexes regarding the overall SMRs in our 
assessment. Data on this are highly controversial: some studies yielded the same results, but 
others found that women have a higher mortality risk (Bronnum-Hansen et al., 2004; 
Kingwell et al., 2012; Leray et al., 2007; Ragonese et al., 2010; Sumelahti et al., 2010). 
Despite this, the relative risk of dying of MS-related causes was higher in women than in men 
in our patients, which was found in case of the evaluations showing higher mortality risk for 
women. It seems, that deaths due to malignancies, hepatic failure and pulmonary emboli are 
less frequent in women than in either men or the general population. A possible causative 
factor may be the higher rate of chronic alcoholism among men, but these results warrant 
further evaluations. 
Both in British Columbia, Canada, and in Western-Norway PPMS patients’ SMR rates and 
relative mortality risks were higher than in RRMS patients (Grytten Torkildsen et al., 2008; 
Kingwell et al., 2012). In our cohort, this difference was far more pronounced: SMR was 4.10 
in PPMS patients while 2.34 in the initially relapsing group. The mortality risk due to MS-
related causes and CVDs were almost twofold, the SMR due to hepatic failure and pulmonary 
emboli was fivefold in patients with PPMS. The differences between the clinical courses 
might explain these great differences. PPMS is more aggressive and patients become 
bedridden far earlier than initially relapsing MS; it starts in older age, so CVDs’ prevalence 
might be higher among these patients. Last but not least, we note that in our cohort the rate of 
PPMS patients was lower than in the Norwegian and the Canadian population (7%, which 
corresponds to only 52 patients vs 10% and 12%), which could bias the results (Grytten 
Torkildsen et al., 2008; Kingwell et al., 2012).  
The median survival time from MS onset was 35 years, 35 years for women and 32 years for 
men. Data from Canadian and Danish cohorts also describe longer median survival times for 
women than men, so our results are in line with the previously published ones (Bronnum-
Hansen et al., 2004; Hader, 2010; Kingwell et al., 2012). PPMS patients’ median survival time 
from MS onset (14 years) is less than half than patients’ with initially relapsing course (35 
years), which is in accordance to previous results (Grytten Torkildsen et al., 2008; Kingwell et 
al., 2012). 
However, since our publication, some interesting new data have arisen. A recent study with 
60-years follow-up period from Norway, published in 2017 showed, that PPMS patients have 
an almost two-fold mortality risk as compared to the RR/SPMS group, and a four-fold risk 
compared to the general population just like in our patients (Lunde et al., 2017). It was also 
revealed in this assessment, that age at disease onset is a crucial factor for life expectancy 
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even more so than we thought before: patients diagnosed at or before the age of 20 years had 
an SMR of 7.3, while patients diagnosed in their sixties had “only” 1.3 (Lunde et al., 2017). 
The most surprising result however shows, that the SMR rates decreased from 3.1 in the 
population with disease onset 1953-1974 to 0.7 in the population diagnosed during the DMT-
era (1997-2012) (Lunde et al., 2017). Similarly, a recent assessment from Sweden, published 
in 2017, encompassing 54 years of follow-up between 1968 and 2012 reported a similarly 
marked decrease in the mortality risk in the last 12 years – while still remaining significantly 
higher than in the general population - as compared to the earlier periods (from a risk of 6.5 
times between 1968-1980 to a risk of 1.7 times between 2001-2012) (Burkill et al., 2017). 
Our study, as well as the previously published assessments were carried out on mixed cohorts 
involving a high proportion of patients who did not receive any therapy for MS, started it at 
the later phases of the disease or could not be changed to more effective therapy when needed 
unlike it can be done in the past couple of years (only about a third of our patients received 
any kind of DMTs). However, it is not due to any kind of mistreatment rather the fact, that the 
first DMTs were introduced in the middle ’90s, and the more effective ones much later (in the 
middle 2000’s or 2010’s). Also, we observed a huge evolution in the diagnostic criteria and 
tools, making the diagnosis of MS far more exact and earlier than before. This means in our 
context, that the previous investigations (including ours) were in high proportion (but not 
exclusively) carried out on patients virtually demonstrating the natural course of disease. In 
the highlighted changing trends, we are probably witnessing the effect of early diagnosis and 
treatment to a degree. Yet – as the Norwegian authors suggested – these results should be 
interpreted cautiously, as the patients from the DMT era are still young, and the effect of 
treatment could not be analysed properly yet. Also, whether this trend is global or will it – 
hopefully - continue forward, still remains to be seen. 
 
V.2. The Hungarian validation of the BICAMS battery 
Cognitive dysfunction is not easy to evaluate, despite being a frequent symptom of MS. To fill 
the need of a screening tool for CI, the BICAMS battery was created in 2011 (Langdon et al., 
2012). During our validation process, we followed the methods proposed by the creators of 
the battery. We found significant differences (p≤0.001 in all tests other than the first CVLT-II 
screening; p=0.017 in the first CVLT-II screening) between the scores of the patients and the 
HC group, and we established good test-retest reliability with strong correlations (r>0.67, 
p<0,001). With this results we conclude, that the Hungarian version of the BICAMS battery is 
valid and useful in the everyday practice. We were the third team to validate and use the 
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battery after the original English, and the Czech (validated in 2012) counterparts (Dusankova 
et al., 2012; Langdon et al., 2012). 
We found slightly lower differences between the test-retest scores and weaker test-retest 
reliability during the CVLT-II test, than the other two screenings in both groups, and it was  
more pronounced in the HC group. We suspected a significant learning effect behind this 
phenomenon. The HC group performed significantly (p=0.020) better at the retest period 
comparing to their original performance than the patients. This difference could solely be 
attributed to their CVLT-II (p=0.003) performance. We suspect the short interval of three 
weeks between the administrations and the use of the same form of the CVLT-II both to be an 
underlying reason (Benedict, 2005; Benedict and Zgaljardic, 1998). Furthermore, probably 
there was no novelty effect during the second administration, thus the anxiety of a new 
situation did not interfere with the performance during screening, further bettering the second 
performance (O'Neil-Pirozzi et al., 2010). The difference between the HC group and the 
patients is harder to explain, but it is a fact, that the control group consisted of individuals 
without any cognitive dysfunction. So we theorize, that despite the relative better performance 
of the MS patients during the retest period, their generally worse cognitive state prevented 
them from improving as much as the HC group, but this needs to be assessed further to be 
stated factually. 
The relationship between fatigue and cognitive decline is not well understood and there are 
not many studies investigating it. Nevertheless, patients often report that fatigue impairs their 
cognitive abilities, yet most of the assessments failed to find any objective connection 
between the two psychopathological symptoms (Bailey et al., 2007; Bol et al., 2010; Johnson 
et al., 1997; Krupp et al., 1988; Morrow et al., 2010; Paul et al., 1998). However, there are 
some sparse data showing that fatigued MS patients’ information processing speed was slower 
than non-fatigued patients’ (Andreasen et al., 2010). Our results may imply similar 
tendencies: overall FIS points showed significant correlations with the patients’ BICAMS 
scores (r<-0.3; p<0.05), and the strongest correlation was shown with the SDMT 
performances. Yet, as we did not investigate causal relationship in multivariable models, we 
cannot draw any clear conclusions further. Also, it is important that our patient pool was 
comprised of only 65 patients, and did not include any progressive PwMS, so evaluation on 
larger and heterogeneous populations are needed to get a clearer picture. 
Since the publication of our study, BICAMS has been validated and adopted to several 
languages and cultures. It is utilized in Europe, North-America, South-America, Iran and 
Japan as well, encompassing 17 nations, with other validation studies under way (Costers et 
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al., 2017; Dusankova et al., 2012; Eshaghi et al., 2012; Filser et al., 2018; Giedraitiene et al., 
2015; Goretti et al., 2014; Niino et al., 2017; O'Connell et al., 2015; Ozakbas et al., 2017; 
Polychroniadou et al., 2016; Sandi et al., 2015; Sousa et al., 2018; Spedo et al., 2015; Strober 
et al., 2009; Vanotti et al., 2016; Walker et al., 2016). In 2017, an Italian centre studied the 
effects of inducting BICAMS results into the cerebral function system of the EDSS score. 
Their results suggests, that a quarter of patients with EDSS≤4 points without integration of 
BICAMS is miscalculated and the disability underestimated (Sacca et al., 2017). Furthermore, 
in 2018, a guideline was proposed for the measurement of cognition in PwMS (Kalb et al., 
2018). BICAMS (along with shorter and longer batteries) has been proposed for routine use. 
These new data further emphasize the usefulness of the battery and the importance of 
measuring CI.  
 
V.3. The prevalence of cognitive impairment and its risk factors among Hungarian 
RRMS and CIS patients 
As we discussed above, the routine assessment of cognition is still in its youth in regard of 
PwMS caused by several factors also described earlier. In our multi-centred evaluation, we 
found the prevalence rate to be 57.1% among the Hungarian MS population, with 58.8% in 
the RRMS group and 25.0% in the CIS group. When published, ours was the second 
prevalence data about CI in PwMS on a representative population cohort and the first to give 
data on CIS patients using the BICAMS battery. The first study with BICAMS was carried 
out by Dusankova and colleges in the Czech Republic in 2012 (Dusankova et al., 2012). They 
found the prevalence rate to be 55%, which is similar to our results and both are within the 
wider range of earlier assessments (43-70%) (Chiaravalloti and DeLuca, 2008; Dusankova et 
al., 2012). Importantly however, our study was carried out on an almost double-sized (553 
patients), homogenous population as compared to the Czech assessment (which involved 
RRMS, RPMS, SPMS and PPMS but not CIS patients) (Dusankova et al., 2012). We did not 
evaluate progressive MS patients, which choice might have even raised the prevalence rate 
further, as CI seems to be even more frequent in the progressive courses (Zakzanis, 2000). 
There are not many data regarding the prevalence of CI in CIS, yet those seem to be in line 
with our findings (Hyncicova et al., 2017). These findings further emphasis the usefulness of 
the Hungarian BICAMS battery and its regular use in clinical routine. 
Information processing speed was the most vulnerable cognitive domain in our evaluation 
(41.7%), followed by visuospatial memory (37.8%) with verbal memory seemingly be less 
affected (13.6%). These results were somewhat expected as other studies demonstrated 
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similar tendencies to various degrees, yet the rate of verbal memory impairment varied more 
than the other domains (Chiaravalloti and DeLuca, 2008). 
The only significant predictive factors for CI was sex, education and the EDSS score 
according to our results, while no association was found with age, age at disease onset and 
disease duration. Earlier assessments were controversial on this matter. Most of the earlier 
studies similarly found sex, education and EDSS scores to be predictive factors, while in 
regard of age at disease onset and disease duration the picture is less clear. Some assessments 
found association with these factors, most, on the other hand, yielded similar results to 
(Amato et al., 2012b; Amato et al., 2006b; Bonnet et al., 2006; DeLuca et al., 2015; Patti et 
al., 2015). The explanation for this is not easy: the different sample-sizes and the utilized 
batteries and methods could be partly responsible for this controversy, yet without further, in 
depth assessments, we do not have a clear answer. Nonetheless, our results – and those in line 
with it - imply that not the disease duration, rather the activity of the disease is the more 
important factor in developing CI, yet – as was said – this is needed to be evaluated further.  
Surprisingly, depression did not significantly affect cognition in our cohort, despite that it has 
been connected to cognitive dysfunction for a long time. However deeper analyses showed, 
that mainly moderate to severe levels of depression have a significant impact on cognitive 
functioning, while in our population of PwMS, the overwhelming majority of depressed 
patients fell into the mild category, explaining this finding (Siegert and Abernethy, 2005).  
According to our results, men are more vulnerable to cognitive dysfunction (70.1%) than 
women (52.0%), and showed higher rate of cognitive impairment in all three evaluated 
domains. Yet, beside their sex, we found no other significant predictors while education and 
EDSS scores differentiated between women. The data on sex differences in MS patients are 
sparse at best. Despite these results show similar differences in the prevalence of CI, to our 
best knowledge, no other study found that education and EDSS score are only predictors in 
women (DeLuca et al., 2015; Patti et al., 2015). The reason behind these differences in 
cognitive functions are even less well studied and understood. Certain genetic variables were 
assessed as factors in developing more serious cognitive dysfunction such as the more 
frequent presence of the Apo-E ε4 allele in men which leads to more severe CI as compared to 
woman – but these evaluations are not specific to MS (Savettieri et al., 2004). Aside from this, 
the role of sex hormones was implied: in particular, a possible protective effect of oestrogens 
on cognitive function was found, but this was reported in other neurodegenerative conditions, 
most notably in Alzheimer’s and Parkinson’s disease, not in MS (Bove et al., 2014; Miller and 
Cronin-Golomb, 2010). Though, as we conducted an epidemiological study and did not 
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evaluate the genetic polymorphisms of the patients, these explanations are merely speculative.  
The prevalence of CI was significantly lower among woman with higher education and lower 
EDSS scores in our study. These findings support previous assessments which established 
EDSS as a possible predictor of CI (Amato et al., 2006b). Also, these studies found that 
higher cognitive reserve associated with higher educational levels is a protective factor 
against cognitive (Amato et al., 2006b; Sumowski et al., 2014; Whalley et al., 2004). 
However, to our best knowledge, no previous assessment concluded that these phenomena are 
restricted to women. These surprising findings might partly be explained by results from MRI 
assessments. We now know, that MS patients suffer a faster rate of brain atrophy both on the 
global as well as in some different local levels (hippocampus, thalamus, basal ganglia) which 
structures show strong association with memory and other cognitive domains (Brass et al., 
2006; DeLuca et al., 2015; Houtchens et al., 2007; Koenig et al., 2014; Morgen et al., 2006). 
Beside this, importantly, our colleges from the Neuroimaging Group (Király et al) showed 
healthy men show faster rate of brain atrophy than healthy women (Kiraly et al., 2016). We 
speculate, that the accelerated atrophy in MS patients combined with this inherently faster 
atrophy rate in men results in the faster disappearance of the cognitive reserve resulting in 
higher susceptibility to cognitive decline. Another important factor that we might consider, 
that male sex itself was shown to be a predictor for worse prognosis in MS patients 
(Weinshenker et al., 1991). It seems, this worse prognosis involves cognition as well. 
In the past decade, some evidence emerged, that CI can possibly be managed. Data on the 
effect of DMTs on cognition is very limited, but in some assessments IFN-β and natalizumab 
showed positive effect regarding the cognitive state (Mattioli et al., 2015; Patti et al., 2013). 
The most promising data comes from cognitive rehabilitation studies, where some marked 
improvements were reported(Amato et al., 2013). Yet, these studies are mostly in the initial 
phases with low number of patients involved and short-time follow-up periods (Amato et al., 
2013). Nevertheless, further evaluations are highly expected in this field and might open up 
new possibilities for treatment, but before this can happen, further, in depth analyses of CI in 
MS are highly needed. 
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VI. Conclusions 
 
VI.1. Mortality and causes of death among Hungarian MS patients 
As conclusion we can state that we are the first to give data on the CoD and the mortality risk 
of PwMS from Central-Eastern Europe.  
We also conclude, that the observed elevated mortality risk in PwMS compared to the general 
population can be solely attributed the disease itself. This is underlined by the fact, that no 
other diseases SMRs were higher than in the general population, and that our results are very 
similar to previous assessments. In fact, those similar data mostly come from North-America 
and Scandinavia, despite the great differences between the social-economic and healthcare 
state of Hungary and these countries (For illustration, the gross domestic product [GDP] per 
capita in Hungary was 13 464 USD in 2013 as compared to 59 950 USD in Denmark and 52 
393 USD in Canada (International Monetary Fund). In 2013, the life expectancy at birth in 
Hungary was 75 years, while it was 80 years in Denmark and 81 years in Canada (World 
Bank)) which shows that the mortality risk does not depend on any other outside factor other 
than MS itself. 
 
VI.2. The Hungarian validation of the BICAMS battery 
We can conclude, based on our results, that the Hungarian version of the BICAMS battery, 
which was the third version of its kind, is valid and can readily be used for the measurement 
of CI. Also, it seems that there can be a connection between fatigue and the cognitive decline 
in PwMS, thus it warrants further research into the topic. 
 
VI.3. The prevalence of cognitive impairment and its risk factors among Hungarian 
RRMS and CIS patients 
Cognitive decline is a frequent, yet still under-diagnosed symptom of MS. Man are more 
susceptible to cognitive decline than women and higher education and lower EDSS scores 
seems to be a protective factor only in women. This is possibly caused by the higher rate of 
brain atrophy leading to the faster elimination of cognitive reserve in men. To our best 
knowledge, we were the first to demonstrate this type of sex-difference in MS patients.  
We confirmed a fairly high prevalence of CI among CIS and RRMS patients who were young, 
active and in relatively good physical condition. This is highly important, because despite a 
patient may seem to be symptom-free during a physical examination, the disease can still be 
active. We know that cognitive problems are one of the main factors determining the QoL of 
PwMS and perhaps the most important factor in the employment state. Thus, we conclude that 
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routine screening of the cognitive state is highly important because it can facilitate the best 
therapeutic decision for the patients thus helping to maintain a good QoL for them. 
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